Skip to main content

Table 2 Seroprevalence of SARS-COV-2 in first (general population) and second phases by city

From: Seroprevalence of SARS-CoV-2 antibody among urban Iranian population: findings from the second large population-based cross-sectional study

City Phases Number, n/N Crude
(95% CI)
Weighted
(95% CI)a
Adjusted for test
performance I
(95% CI)b
Adjusted for test
performance II
(95% CI)c
Ahvaz First phase 8/100 8.0 (3.5-15.5) 7.9 (2.2-15.9) 9.4 (0.7-21.6) 8.7 (0.6-20.1)
Second phase 57/393 14.5 (11.2-18.4) 17.7 (5.1-30.3) 20.4 (0.5-40.2) 18.9 (0.6-37.2)
Ardabil First phase 11/87 12.6 (6.5-21.5) 14.8 (3.9-32.3) 20.0 (3.2-46.8) 18.6 (3.0-43.5)
Second phase 115/384 29.9 (25.4-34.8) 28.8 (22.8-34.8) 34.1 (24.2-44.0) 31.7 (22.7-40.7)
Babol First phase 19/91 20.9 (13.1-30.7) 16.4 (9.6-24.6) 22.4 (11.9-35.1) 20.8 (11.1-32.6)
Second phase 100/383 26.1 (21.8-30.8) 23.1 (14.3-31.8) 27.0 (16.6-37.4) 25.1 (15.3-34.9)
Gorgan First phase 41/125 32.8 (24.7-41.8) 30.4 (22.3-39.7) 43.9 (31.4-58.3) 40.9 (29.2-54.2)
Second phase 62/330 18.8 (14.7-23.4) 22.4 (10.7-34.1) 26.1 (6.9-45.4) 24.3 (6.9-41.7)
Hamedan First phase 8/108 7.4 (3.5-15.2) 7.2 (2.9-12.9) 8.3 (1.6-17.0) 7.7 (1.5-15.8)
Second phase 116/391 29.7 (25.2-34.5) 27.5 (21.7-33.3) 32.4 (22.3-42.6) 30.1 (20.7-39.6)
Kerman First phase 10/108 9.3 (4.5-16.4) 7.1 (3.2-12.6) 8.2 (2.2-16.6) 7.7 (2.1-15.4)
Second phase 64/355 18.0 (14.2-22.4) 14.5 (9.3-19.7) 16.0 (10.7-21.4) 14.9 (9.8-20.0)
Kermanshah First phase 14/133 10.6 (5.9-17.1) 13.1 (5.3-21.9) 17.3 (5.3-30.9) 16.1 (4.9-28.8)
Second phase 92/389 23.6 (19.5-28.2) 24.1 (17.4-30.7) 28.3 (15.9-40.7) 26.3 (14.5-38.1)
Mashhad First phase 21/176 11.9 (7.5-17.6) 11.5 (7.1-16.8) 14.8 (8.2-23.1) 13.8 (7.6-21.5)
Second phase 171/691 24.7 (21.6-28.1) 24.7 (17.7-31.7) 35.2 (23.6-46.8) 32.7 (21.2-44.2)
Qom First phase 48/108 44.4 (34.8-54.3) 39.9 (26.0-56.4) 58.5 (37.2-83.9) 54.4 (34.6-78.0)
Second phase 114/385 29.6 (25.1-34.4) 27.2 (18.1-36.2) 29.8 (24.0-35.6) 32.0 (25.9-38.2)
Sanandaj First phase 4/96 4.2 (1.1-10.3) 2.7 (0.6-5.7) 1.7 (0.0-6.0) 1.6 (0.0-5.6)
Second phase 117/388 30.1 (25.6-35.0) 27.9 (22.2-33.6) 33.0 (27.3-38.6) 30.7 (25.3-36.1)
Sari First phase 22/175 12.6 (8.0-18.4) 11.4 (6.9-16.4) 14.7 (7.8-22.4) 13.7 (7.3-20.8)
Second phase 74/400 18.5 (14.8-22.7) 15.9 (9.0-22.7) 17.8 (11.0-24.5) 16.5 (9.8-23.2)
Shiraz First phase 10/124 8.1 (3.9-15.0) 6.6 (2.6-11.20 7.3 (1.2-14.5) 6.8 (1.1-13.5)
Second phase 90/485 18.6 (15.2-22.3) 18.1 (13.1-23.2) 25.4 (13.6-37.1) 23.6 (12.5-34.7)
Tabriz First phase 8/103 7.8 (3.4-14.7) 5.4 (1.7-10.2) 5.6 (0.0-13.0) 5.2 (0.0-12.1)
Second phase 180/485 37.1 (32.8-41.6) 32.8 (24.7-40.8) 39.2 (33.0-45.5) 36.5 (30.8-42.2)
Tehran First phase 191/1572 12.1 (10.6-13.9) 12.4 (10.6-14.5) 16.3 (13.5-19.5) 15.1 (12.5-18.2)
Second phase 271/1181 22.9 (20.6-25.4) 24.9 (20.0-29.8) 35.5 (27.1-43.9) 33.0 (25.0-41.0)
Urmia First phase 8/101 7.9 (3.5-15.0) 8.4 (1.9-17.6) 10.0 (0.2-24.3) 9.3 (0.2-22.6)
Second phase 66/389 17.0 (13.4-21.1) 18.4 (12.4-24.3) 20.8 (9.0-32.5) 19.3 (8.2-30.4)
Zahedan First phase 8/105 7.6 (3.3-14.5) 9.7 (3.3-16.9) 12.1 (2.3-23.3) 11.3 (2.1-21.6)
Second phase 75/382 19.6 (15.8-24.0) 16.2 (9.8-22.6) 18.0 (7.6-28.4) 16.7 (7.3-26.1)
  1. Seroprevalence data are % (95% confidence interval). aWeighted by age and sex for each city population·bWeighted prevalence adjusted for test performance I (sensitivity 66·9% and specificity 98.2%). cWeighted prevalence adjusted for test performance II as reported by manufacturer (sensitivity 71.8% and specificity 98.2%). Sample sizes of the first and second phases were 3530 and 7411, respectively